Literature DB >> 21744056

Glucocorticoid-induced hypertension.

Julie E Goodwin1, David S Geller.   

Abstract

Glucocorticoid-induced hypertension is a common clinical problem that is poorly understood, thus rendering treatment strategies sub-optimal. This form of hypertension has been commonly thought to be mediated by excess sodium and water reabsorption by the renal mineralocorticoid receptor. However, experimental and clinical data in both humans and animal models suggest important roles for the glucocorticoid receptor as well, in both the pathogenesis and maintenance of this hypertension. The glucocorticoid receptor is widely expressed in a number of organ systems relevant to blood pressure regulation, including the kidney, the brain and the vasculature. In vitro studies in isolated kidney tissues as well as in vascular smooth muscle and vascular endothelial cells have attempted to elucidate the molecular physiology of glucocorticoid-induced hypertension, but have generally been limited by the inability to study signaling pathways in an intact organism. More recently, the power of mouse genetics has been employed to examine the tissue-specific contributions of vascular and extra-vascular tissues to this form of hypertension. Here we review recent developments in our understanding of the pathogenesis of glucocorticoid-induced hypertension.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21744056     DOI: 10.1007/s00467-011-1928-4

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  62 in total

1.  24-hour profiles of blood pressure and heart rate in Cushing's syndrome: relationship between cortisol and cardiovascular rhythmicities.

Authors:  A Piovesan; M Panarelli; M Terzolo; G Osella; C Matrella; P Paccotti; A Angeli
Journal:  Chronobiol Int       Date:  1990       Impact factor: 2.877

2.  Knockout of the vascular endothelial glucocorticoid receptor abrogates dexamethasone-induced hypertension.

Authors:  Julie E Goodwin; Junhui Zhang; David Gonzalez; Sebastian Albinsson; David S Geller
Journal:  J Hypertens       Date:  2011-07       Impact factor: 4.844

3.  Role of antiglucocorticoid RU 486 on dexamethasone-induced hypertension in rats.

Authors:  M Kalimi
Journal:  Am J Physiol       Date:  1989-05

4.  Down-regulation of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated hypertension.

Authors:  T Wallerath; K Witte; S C Schäfer; P M Schwarz; W Prellwitz; P Wohlfart; H Kleinert; H A Lehr; B Lemmer; U Förstermann
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

5.  Cardiovascular target organ damage in essential hypertensives with or without reproducible nocturnal fall in blood pressure.

Authors:  Cesare Cuspidi; Stefano Meani; Maurizio Salerno; Cristiana Valerio; Veronica Fusi; Barbara Severgnini; Laura Lonati; Fabio Magrini; Alberto Zanchetti
Journal:  J Hypertens       Date:  2004-02       Impact factor: 4.844

6.  Glucocorticoids decrease GTP cyclohydrolase and tetrahydrobiopterin-dependent vasorelaxation through glucocorticoid receptors.

Authors:  Brett M Mitchell; Anne M Dorrance; Eniki A Mack; R Clinton Webb
Journal:  J Cardiovasc Pharmacol       Date:  2004-01       Impact factor: 3.105

7.  Increased expression of vascular angiotensin II type 1A receptor gene in glucocorticoid-induced hypertension.

Authors:  A Sato; H Suzuki; Y Nakazato; H Shibata; T Inagami; T Saruta
Journal:  J Hypertens       Date:  1994-05       Impact factor: 4.844

8.  Exogenous glucocorticoid eliminates or reverses circadian blood pressure variations.

Authors:  Y Imai; K Abe; S Sasaki; N Minami; M Munakata; M Nihei; H Sekino; K Yoshinaga
Journal:  J Hypertens       Date:  1989-02       Impact factor: 4.844

9.  Study on the mechanisms of glucocorticoid-induced hypertension: glucocorticoids increase transmembrane Ca2+ influx in vascular smooth muscle in vivo.

Authors:  L Kornel; A V Prancan; N Kanamarlapudi; J Hynes; E Kuzianik
Journal:  Endocr Res       Date:  1995 Feb-May       Impact factor: 1.720

10.  Characterization of a novel gain of function glucocorticoid receptor knock-in mouse.

Authors:  Junhui Zhang; Renshang Ge; Catherine Matte-Martone; Julie Goodwin; Warren D Shlomchik; Mark J Mamula; Ali Kooshkabadi; Matthew P Hardy; David Geller
Journal:  J Biol Chem       Date:  2008-11-18       Impact factor: 5.157

View more
  38 in total

Review 1.  Sustained-release steroids for the treatment of diabetic macular edema.

Authors:  Alejandra Daruich; Alexandre Matet; Francine Behar-Cohen
Journal:  Curr Diab Rep       Date:  2015-11       Impact factor: 4.810

Review 2.  Comprehensive review of cardiovascular toxicity of drugs and related agents.

Authors:  Přemysl Mladěnka; Lenka Applová; Jiří Patočka; Vera Marisa Costa; Fernando Remiao; Jana Pourová; Aleš Mladěnka; Jana Karlíčková; Luděk Jahodář; Marie Vopršalová; Kurt J Varner; Martin Štěrba
Journal:  Med Res Rev       Date:  2018-01-05       Impact factor: 12.944

3.  Ambulatory blood pressure monitoring-derived short-term blood pressure variability is increased in Cushing's syndrome.

Authors:  Andrea Rebellato; Andrea Grillo; Francesca Dassie; Nicoletta Sonino; Pietro Maffei; Chiara Martini; Agostino Paoletta; Bruno Fabris; Renzo Carretta; Francesco Fallo
Journal:  Endocrine       Date:  2014-01-10       Impact factor: 3.633

4.  Longterm blood pressure variability in patients with rheumatoid arthritis and its effect on cardiovascular events and all-cause mortality in RA: a population-based comparative cohort study.

Authors:  Elena Myasoedova; Cynthia S Crowson; Abigail B Green; Eric L Matteson; Sherine E Gabriel
Journal:  J Rheumatol       Date:  2014-07-01       Impact factor: 4.666

5.  Posterior reversible encephalopathy syndrome: characteristics, diagnostic accuracy, prognostic factors and long-term outcome in a paediatric population.

Authors:  Catarina Marques Duarte; Ana Sofia Vilardouro; Duarte Rebelo; Sofia Quintas; Francisco Abecasis
Journal:  Acta Neurol Belg       Date:  2021-10-24       Impact factor: 2.396

6.  Argininosuccinate Lyase Deficiency Causes an Endothelial-Dependent Form of Hypertension.

Authors:  Jordan Kho; Xiaoyu Tian; Wing-Tak Wong; Terry Bertin; Ming-Ming Jiang; Shan Chen; Zixue Jin; Oleg A Shchelochkov; Lindsay C Burrage; Anilkumar K Reddy; Hong Jiang; Reem Abo-Zahrah; Shuangtao Ma; Ping Zhang; Karl-Dimiter Bissig; Jean J Kim; Sridevi Devaraj; George G Rodney; Ayelet Erez; Nathan S Bryan; Sandesh C S Nagamani; Brendan H Lee
Journal:  Am J Hum Genet       Date:  2018-08-02       Impact factor: 11.025

Review 7.  A new paradigm: Diagnosis and management of HSCT-associated thrombotic microangiopathy as multi-system endothelial injury.

Authors:  Sonata Jodele; Benjamin L Laskin; Christopher E Dandoy; Kasiani C Myers; Javier El-Bietar; Stella M Davies; Jens Goebel; Bradley P Dixon
Journal:  Blood Rev       Date:  2014-11-28       Impact factor: 8.250

8.  Elevated corticosterone in the dorsal hindbrain increases plasma norepinephrine and neuropeptide Y, and recruits a vasopressin response to stress.

Authors:  Daisy L Daubert; Benjamin M Looney; Rebekah R Clifton; Jake N Cho; Deborah A Scheuer
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-05-14       Impact factor: 3.619

Review 9.  Polypharmacy in Older Adults With Hypertension: A Comprehensive Review.

Authors:  Bertrand N Mukete; Keith C Ferdinand
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-07-27       Impact factor: 3.738

Review 10.  The Use of the Anticoagulant Heparin and Corticosteroid Dexamethasone as Prominent Treatments for COVID-19.

Authors:  Heloísa Antoniella Braz-de-Melo; Sara Socorro Faria; Gabriel Pasquarelli-do-Nascimento; Igor de Oliveira Santos; Gary P Kobinger; Kelly Grace Magalhães
Journal:  Front Med (Lausanne)       Date:  2021-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.